Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
The Spectrum of Brca1 and Brca2 Pathogenic Sequence Variants in Middle Eastern, North African, and South European Countries Publisher Pubmed



Laitman Y1 ; Friebel TM2 ; Yannoukakos D3 ; Fostira F3 ; Konstantopoulou I3 ; Figlioli G4 ; Bonanni B5 ; Manoukian S6 ; Zuradelli M7 ; Tondini C8 ; Pasini B9 ; Peterlongo P4 ; Plaseskakaranfilska D10 ; Jakimovska M10 Show All Authors
Authors
  1. Laitman Y1
  2. Friebel TM2
  3. Yannoukakos D3
  4. Fostira F3
  5. Konstantopoulou I3
  6. Figlioli G4
  7. Bonanni B5
  8. Manoukian S6
  9. Zuradelli M7
  10. Tondini C8
  11. Pasini B9
  12. Peterlongo P4
  13. Plaseskakaranfilska D10
  14. Jakimovska M10
  15. Majidzadeh K11
  16. Zarinfam S11
  17. Loizidou MA12
  18. Hadjisavvas A12
  19. Michailidou K12
  20. Kyriacou K12
  21. Behar DM13
  22. Molho RB14, 15
  23. Ganz P16
  24. James P17
  25. Parsons MT18
  26. Sallam A19
  27. Olopade OI19
  28. Seth A20
  29. Chenevix Trench G18
  30. Leslie G21
  31. Mcguffog L21
  32. Marafie MJ22
  33. Megarbane A23
  34. Almulla F24
  35. Rebbeck TR2, 25
  36. Friedman E1, 15

Source: Human Mutation Published:2019


Abstract

BRCA1 BRCA2 mutational spectrum in the Middle East, North Africa, and Southern Europe is not well characterized. The unique history and cultural practices characterizing these regions, often involving consanguinity and inbreeding, plausibly led to the accumulation of population-specific founder pathogenic sequence variants (PSVs). To determine recurring BRCA PSVs in these locales, a search in PUBMED, EMBASE, BIC, and CIMBA was carried out combined with outreach to researchers from the relevant countries for unpublished data. We identified 232 PSVs in BRCA1 and 239 in BRCA2 in 25 of 33 countries surveyed. Common PSVs that were detected in four or more countries were c.5266dup (p.Gln1756Profs), c.181T>G (p.Cys61Gly), c.68_69del (p.Glu23Valfs), c.5030_5033del (p.Thr1677Ilefs), c.4327C>T (p.Arg1443Ter), c.5251C>T (p.Arg1751Ter), c.1016dup (p.Val340Glyfs), c.3700_3704del (p.Val1234Glnfs), c.4065_4068del (p.Asn1355Lysfs), c.1504_1508del (p.Leu502Alafs), c.843_846del (p.Ser282Tyrfs), c.798_799del (p.Ser267Lysfs), and c.3607C>T (p.Arg1203Ter) in BRCA1 and c.2808_2811del (p.Ala938Profs), c.5722_5723del (p.Leu1908Argfs), c.9097dup (p.Thr3033Asnfs), c.1310_1313del (p. p.Lys437Ilefs), and c.5946del (p.Ser1982Argfs) for BRCA2. Notably, some mutations (e.g., p.Asn257Lysfs (c.771_775del)) were observed in unrelated populations. Thus, seemingly genotyping recurring BRCA PSVs in specific populations may provide first pass BRCA genotyping platform. © 2019 Wiley Periodicals, Inc.